Cadrenal Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Cadrenal Therapeutics, Inc. (CVKD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $12.80 per share for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-08-13
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-03-31 was $12.93, a 1386.21% increase year-over-year.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-03-31 was $0.87, a 21.62% decline year-over-year.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-03-31 was $1.11.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $12.67, a 1062.39% increase from fiscal 2023.
- Cadrenal Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $1.09.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 11 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $12.80 10-Q · filed 2026-08-13 | ||||
| 2025-09-30 | $12.93 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $12.93 10-Q · filed 2025-08-11 | ||||
| 2025-03-31 | $12.93 10-Q · filed 2025-05-08 | ||||
| 2024-12-31 | $12.67 10-K · filed 2025-03-13 | ||||
| 2024-09-30 | $12.67 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $0.82 10-Q · filed 2024-08-07 | ||||
| 2024-03-31 | $0.87 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | $1.09 10-K · filed 2024-03-11 | ||||
| 2023-09-30 | $1.09 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $1.11 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $1.11 10-Q · filed 2023-05-10 | ||||
| 2022-12-31 | $1.11 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |